Corbus Pharmaceuticals Holdings Inc (CRBP)

Apr 14, 2026

Corbus Pharmaceuticals (CRBP) Advances in Obesity Treatment Tria - GuruFocus

Apr 14, 2026

Apr 14, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Apr 14, 2026

Apr 14, 2026

Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone - TipRanks

Apr 14, 2026

Apr 14, 2026

Corbus completes enrollment in obesity drug trial - Investing.com

Apr 14, 2026

Apr 14, 2026

Corbus Pharmaceuticals Holdings initiates last patient first visit in CANYON-1 obesity trial with 240 participants - Traders Union

Apr 14, 2026

Apr 14, 2026

Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity - The Manila Times

Apr 14, 2026

Apr 14, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) reaches key Phase 1b obesity trial milestone for CRB-913 - Stock Titan

Apr 14, 2026

Apr 14, 2026

Corbus hits 240-patient milestone for oral obesity drug study - Stock Titan

Apr 14, 2026

Apr 14, 2026

Behavioral Patterns of CRBP and Institutional Flows - Stock Traders Daily

Apr 14, 2026

Apr 13, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 13, 2026

Apr 11, 2026

Corbus reaches FDA agreement on development path for cancer drug CRB-701 - MSN

Apr 11, 2026

Apr 10, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch

Apr 10, 2026

Apr 10, 2026

CRBP Stock Price, Quote & Chart | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill

Apr 10, 2026

Apr 09, 2026

Published on: 2026-04-09 22:47:10 - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Corbus Pharmaceuticals Holdings Inc. stock rises Wednesday, still underperforms market - MarketWatch

Apr 08, 2026

Apr 08, 2026

Corbus Pharmaceuticals Holdings, Inc. secures ASCO 2026 slot for new CRB-701 clinical findings - Traders Union

Apr 08, 2026

Apr 08, 2026

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer - Sahm

Apr 08, 2026

Apr 08, 2026

Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Sahm

Apr 08, 2026

Apr 07, 2026

Jefferies reiterates Corbus Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada

Apr 07, 2026

Apr 07, 2026

Corbus Pharmaceuticals Secures FDA Alignment on Accelerated Approval Path for CRB-701 in Head and Neck and Cervical Cancer 1 - Minichart

Apr 07, 2026

Apr 07, 2026

Corbus Pharmaceuticals (CRBP) Aligns with FDA on CRB-701 Study P - GuruFocus

Apr 07, 2026

Apr 07, 2026

Corbus Aligns With FDA on CRB-701 Registrational Path - TipRanks

Apr 07, 2026

Apr 07, 2026

Corbus Pharmaceuticals Holdings, Inc. secures U.S. FDA alignment on CRB-701 study for HNSCC and cervical cancer - Traders Union

Apr 07, 2026

Apr 07, 2026

FDA backs Corbus (NASDAQ: CRBP) CRB-701 registrational plans in HNSCC and cervical cancer - Stock Titan

Apr 07, 2026

Apr 07, 2026

Corbus Pharmaceuticals announces broad alignment with FDA on registration path for CRB-701 in second-line HNSCC and cervical cancer - marketscreener.com

Apr 07, 2026

Apr 06, 2026

Mizuho raises Corbus Pharmaceuticals stock price target on CRB-701 By Investing.com - Investing.com Canada

Apr 06, 2026

Apr 03, 2026

(CRBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Apr 03, 2026

Apr 02, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) seeks approval to expand equity plan and confirm pay policies - stocktitan.net

Apr 02, 2026

Apr 02, 2026

Corbus Pharmaceuticals Holdings (3371.SG) stock price, news, quote and history - Yahoo Finance UK

Apr 02, 2026

Apr 02, 2026

Corbus Pharmaceuticals Holdings, Inc. advances next-gen ADC targeting Nectin-4 in aggressive cancers - Traders Union

Apr 02, 2026

Apr 02, 2026

Mizuho raises Corbus Pharmaceuticals stock price target on updated CRB-701 assumptions - Investing.com Canada

Apr 02, 2026

Apr 01, 2026

CRBP PE Ratio & Valuation, Is CRBP Overvalued - Intellectia AI

Apr 01, 2026

Mar 31, 2026

CEO Change: What is the cash position of Corbus Pharmaceuticals Holdings Inc2026 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Published on: 2026-03-31 10:02:36 - baoquankhu1.vn

Mar 30, 2026

Mar 30, 2026

Aug Shorts: Can Corbus Pharmaceuticals Holdings Inc ride the EV waveWeekly Trend Summary & Daily Technical Forecast Reports - baoquankhu1.vn

Mar 30, 2026

Mar 30, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch

Mar 30, 2026

Mar 28, 2026

STU:3371 PB Ratio: 1.04 — 73% Below Median - gurufocus.com

Mar 28, 2026

Mar 27, 2026

CRBP SEC FilingsCorbus Pharmaceu 10-K, 10-Q, 8-K Forms - stocktitan.net

Mar 27, 2026

Mar 25, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Mar 25, 2026

Mar 25, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf to sell equity, debt - Stock Titan

Mar 25, 2026

Mar 25, 2026

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat

Mar 25, 2026

Mar 24, 2026

Corbus Pharmaceuticals Holdings Repeat Insider Selling Not A Positive Indicator - simplywall.st

Mar 24, 2026

Mar 23, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 23, 2026

Mar 23, 2026

Corbus Pharmaceuticals Holdings, Inc. to present CRB-913 oral CB1 inverse agonist at BMO Summit - Traders Union

Mar 23, 2026

Mar 23, 2026

[EFFECT] Corbus Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan

Mar 23, 2026

Mar 23, 2026

How (CRBP) Movements Inform Risk Allocation Models - Stock Traders Daily

Mar 23, 2026